Tear proteomics analysis of patient suffered from delayed mustard gas keratopathy.
Ocular complications
Proteomics
Sulfur mustard
Tear
Journal
Proteome science
ISSN: 1477-5956
Titre abrégé: Proteome Sci
Pays: England
ID NLM: 101170539
Informations de publication
Date de publication:
10 Aug 2022
10 Aug 2022
Historique:
received:
18
12
2021
accepted:
03
08
2022
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
11
8
2022
Statut:
epublish
Résumé
Understanding the molecular and cellular mechanisms involved in the pathogenesis of ocular injured induced by mustard gas can help better identify complications and discover appropriate therapies. This study aimed to analyze the proteomics of tears of chemical warfare victims with mustard gas ocular injuries and compare it with healthy individuals. In this case-control research, 10 mustard gas victims with long-term ocular difficulties (Chronic) were included in the patient group, while 10 healthy persons who were age and sex matched to the patients were included in the control group. Schirmer strips were used to collect the tears of the participants. Proteomics experiments were performed using the high-efficiency TMT10X method to evaluate the tear protein profile, and statistical bioinformatics methods were used to identify the differently expressed proteins. 24 proteins had different expressions between the two groups. Among these 24 proteins, 8 proteins had increased expression in veterans' tears, while the remaining 16 proteins had decreased expression. Reactome pathways were used to look at proteins with various expressions, and 13 proteins were found to be engaged in the immune system, 9 of which were effective in the innate immune system, and 5 proteins were effective in the complement cascade. Ocular mustard gas exposure may cause a compromised immune system on the eye's surface, exposing the cornea to external and endogenous infections, and eventually causing corneal opacity and reduced vision.
Identifiants
pubmed: 35948930
doi: 10.1186/s12953-022-00195-1
pii: 10.1186/s12953-022-00195-1
pmc: PMC9364592
doi:
Types de publication
Journal Article
Langues
eng
Pagination
13Informations de copyright
© 2022. The Author(s).
Références
J Proteome Res. 2009 Nov;8(11):4889-905
pubmed: 19705875
Int J Mol Sci. 2019 Apr 19;20(8):
pubmed: 31010136
J Ophthalmic Vis Res. 2014 Oct-Dec;9(4):417-22
pubmed: 25709764
Prog Histochem Cytochem. 2006;41(1):1-53
pubmed: 16798129
Prog Retin Eye Res. 2018 Nov;67:150-167
pubmed: 29758268
Dev Ophthalmol. 2010;45:1-11
pubmed: 20502021
J Cell Biochem. 2018 Jan;119(1):197-206
pubmed: 28657650
Ocul Surf. 2011 Jul;9(3):163-78
pubmed: 21791191
Curr Eye Res. 2000 Nov;21(5):856-66
pubmed: 11262607
Ophthalmology. 2005 Apr;112(4):617-25
pubmed: 15808253
Basic Clin Pharmacol Toxicol. 2006 Oct;99(4):273-82
pubmed: 17040211
Invest Ophthalmol Vis Sci. 1993 Dec;34(13):3579-84
pubmed: 7505007
Peptides. 2004 May;25(5):819-25
pubmed: 15177877
Cornea. 2009 Dec;28(10):1109-17
pubmed: 19770725
J Biol Chem. 2008 May 9;283(19):13418-27
pubmed: 18326859
PLoS One. 2014 Nov 18;9(11):e113310
pubmed: 25405607
J Proteomics. 2020 Aug 15;225:103881
pubmed: 32565161
Invest Ophthalmol Vis Sci. 2009 Aug;50(8):3794-801
pubmed: 19255155
Ann Emerg Med. 1992 Mar;21(3):303-8
pubmed: 1536492
Optom Vis Sci. 2015 Sep;92(9):931-8
pubmed: 26267059
Sci Rep. 2017 Dec 12;7(1):17478
pubmed: 29234088
BMC Genomics. 2005 Oct 20;6:145
pubmed: 16242023
Mol Vis. 2008 Mar 12;14:500-7
pubmed: 18385783
Mol Biosyst. 2013 Jun;9(6):1108-16
pubmed: 23580065
Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3492-502
pubmed: 11006244
Invest Ophthalmol Vis Sci. 2014 May 08;55(5):3037-42
pubmed: 24713479
J Cell Biochem. 2017 Nov;118(11):3549-3560
pubmed: 28106291
Sci Rep. 2018 Nov 16;8(1):16936
pubmed: 30446693
Crit Rev Biochem Mol Biol. 2017 Feb;52(1):45-56
pubmed: 27841019
Chem Biol Interact. 1998 Mar 12;110(1-2):57-70
pubmed: 9566725
Toxicology. 2005 Oct 30;214(3):198-209
pubmed: 16084004
Mass Spectrom Rev. 2018 Sep;37(5):583-606
pubmed: 29120501
Invest Ophthalmol Vis Sci. 2012 Jul 31;53(8):5052-9
pubmed: 22736608
Invest Ophthalmol Vis Sci. 1996 Jul;37(8):1576-81
pubmed: 8675400
Crit Rev Toxicol. 2011 May;41(5):384-403
pubmed: 21329486
Fundam Clin Pharmacol. 2005 Dec;19(6):713-21
pubmed: 16313284
Chem Immunol Allergy. 2007;92:27-35
pubmed: 17264480